Motif FoodWorks Inc v. Impossible Foods Inc

1. Case Identification

• Case #: IPR2023-00207
• Patent #: 11,273,127
• Filed: November 22, 2022
• Petitioner(s): Amneal Pharmaceuticals LLC
• Patent Owner(s): Jazz Pharmaceuticals, Inc.
• Challenged Claims: 1-13

2. Patent Overview

• Title: Oxybate Formulations And Methods Of Use
• Brief Description: The ’127 patent discloses pharmaceutical compositions comprising mixed salts of gamma-hydroxybutyrate (oxybate) for treating narcolepsy. The compositions are designed to have a reduced sodium content by substituting a portion of the sodium cations with other physiologically acceptable cations, such as potassium, calcium, and magnesium, thereby lowering the total sodium load for the patient compared to traditional sodium oxybate monotherapy.

3. Grounds for Unpatentability

Ground 1: Obviousness over Mamelak and POSA Knowledge - Claims 1-13 are obvious over Mamelak in view of the general knowledge of a Person of Ordinary Skill in the Art (POSA).

• Prior Art Relied Upon: Mamelak (Patent 8,580,845) and the general knowledge of a POSA.
• Core Argument for this Ground:
  • Prior Art Mapping: Petitioner argued that Mamelak disclosed the core elements of the challenged claims, including methods for treating narcolepsy by administering gamma-hydroxybutyrate (GHB) at a total daily dose of 4.5 g to 9 g, split into two doses. The key difference was that Mamelak focused on sodium oxybate (a single-cation salt), whereas the ’127 patent claims compositions with a mix of sodium, potassium, calcium, and magnesium cations to achieve specific percentage ranges. Petitioner asserted that a POSA at the time would have been well aware of the significant health risks associated with high sodium intake, such as hypertension and cardiovascular disease, which was a known problem with the high doses of sodium oxybate required for therapy.
  • Motivation to Combine: The motivation was to solve the well-documented problem of excessive sodium loading from existing sodium oxybate products (like Xyrem®). A POSA would have been directly motivated to apply the routine and well-understood formulation strategy of ionic substitution (or cation exchange) to Mamelak's sodium oxybate therapy. This would involve replacing a portion of the sodium cations with other common, safe, and physiologically acceptable cations (K+, Mg2+, Ca2+) to reduce the overall sodium burden on the patient while maintaining the therapeutic effect of the oxybate anion.
  • Expectation of Success: A POSA would have a high expectation of success. Substituting common cations like potassium, magnesium, and calcium for sodium in a salt formulation was a conventional, predictable, and routine technique in pharmaceutical development. The properties of these alternative cations were well-characterized, and their use in oral solutions was common, presenting no significant technical hurdles.

Ground 2: Obviousness over Mamelak and CADD - Claims 1-13 are obvious over Mamelak in view of CADD.

• Prior Art Relied Upon: Mamelak (Patent 8,580,845) and CADD (Application # 2010/0056619).
• Core Argument for this Ground:
  • Prior Art Mapping: This ground built upon the teachings of Mamelak as the base reference for GHB therapy. Petitioner argued that CADD provided the explicit missing element: a teaching of mixed-cation GHB salt formulations to reduce cation load. CADD expressly disclosed creating GHB compositions containing a mixture of salts, including sodium, potassium, calcium, and magnesium, for the stated purpose of reducing the amount of any single cation administered. CADD's teaching provided a direct blueprint for the specific cation-diversified formulations claimed in the ’127 patent.
  • Motivation to Combine: The motivation was explicit in CADD itself, which taught creating mixed-salt GHB formulations to "reduce the amount of a single cation." A POSA, recognizing the sodium load problem in Mamelak's therapy, would be motivated to apply CADD's specific solution for reducing cation load directly to Mamelak's method. The combination represented the application of a known technique (from CADD) to a known problem (in Mamelak's therapy) to achieve a predictable result.
  • Expectation of Success: The expectation of success was exceptionally high because CADD did not just suggest cation substitution in general but specifically taught creating mixed-salt formulations of GHB with the very same cations recited in the challenged claims. This provided a POSA with a clear and direct path to the claimed invention with no undue experimentation required.
• Additional Grounds: Petitioner asserted additional obviousness challenges based on combinations of Mamelak with the Xyrem® Label and general POSA knowledge, as well as a four-way combination of Mamelak, CADD, the Xyrem® Label, and POSA knowledge, all relying on similar rationales for reducing sodium load.

4. Key Claim Construction Positions

• "total daily dose" (claims 1, 8): Petitioner argued this term should be construed as "the total amount of gamma-hydroxybutyrate administered over a 24-hour period." This construction was asserted to be consistent with the specification and the understanding of a POSA. Petitioner contended this interpretation was critical for comparing the claimed dosage ranges to the disclosures in the prior art, which described GHB dosages in a similar manner.

5. Arguments Regarding Discretionary Denial

• Petitioner argued against discretionary denial under both 35 U.S.C. §325(d) and §314(a) (Fintiv).
• §325(d): Petitioner contended that the core prior art references, particularly CADD, were not before the Examiner during prosecution. Because these references presented a much stronger and more direct case for obviousness than the art considered by the USPTO, the petition raised new issues warranting review.
• Fintiv Factors: Petitioner argued that the parallel district court litigation was in its infancy, with no trial date set and minimal discovery completed. Therefore, an IPR would resolve patentability issues far more efficiently and with less burden on the parties and the judicial system than the co-pending litigation.

6. Relief Requested

• Petitioner requests institution of an inter partes review and cancellation of claims 1-13 of the ’127 patent as unpatentable.